Zeer Glaukos / intent / glaukos

Glaukos

1001-5000 employees·Aliso Viejo, California, United States·glaukos.com

Observed, not inferred · updated weekly

Buying intent

36 tracked signals | Top 15 topics are below | Marketing and Sales are carrying most of it.

25signals · 30 days
26topics tracked
18.75%attributed to a team

Attention by team

LinkedIn activity, by team

Where Glaukos's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.

Patient Care
Health Care
Employer Branding
Career Development
Hiring
Data Analytics
Marketing
Medium50% of team Marketing to Patient Care: Medium, 50% of this team's signals
Medium50% of team Marketing to Health Care: Medium, 50% of this team's signals
Marketing to Employer Branding: no signal
Marketing to Career Development: no signal
Marketing to Hiring: no signal
Marketing to Data Analytics: no signal
Sales
Sales to Patient Care: no signal
Sales to Health Care: no signal
Sales to Employer Branding: no signal
Medium100% of team Sales to Career Development: Medium, 100% of this team's signals
Sales to Hiring: no signal
Sales to Data Analytics: no signal
Others
High23% of team Others to Patient Care: High, 23% of this team's signals
High23% of team Others to Health Care: High, 23% of this team's signals
High15% of team Others to Employer Branding: High, 15% of this team's signals
Medium8% of team Others to Career Development: Medium, 8% of this team's signals
High15% of team Others to Hiring: High, 15% of this team's signals
High15% of team Others to Data Analytics: High, 15% of this team's signals
LowMediumHigh·  banded against the busiest pairing on this page

Topics being researched

30-day window

Every tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.

Patient Care
LinkedIn
High volume
96%
last
11d ago
Health Care
LinkedIn
High volume
94%
last
11d ago
Employer Branding
LinkedIn
Medium volume
98%
last
12d ago
Career Development
LinkedIn
Medium volume
98%
last
12d ago
Hiring
LinkedIn
Medium volume
95%
last
12d ago
Data Analytics
LinkedIn
Medium volume
96%
last
11d ago
Pharmaceuticals
LinkedIn
Low volume
94%
last
11d ago
Talent Management
LinkedIn
Low volume
98%
last
11d ago
Physical Security
LinkedIn
Low volume
98%
last
11d ago
Tableau
LinkedIn
Low volume
92%
last
11d ago
Machine Learning
LinkedIn
Low volume
98%
last
24d ago
Nuclear Medicine
LinkedIn
Low volume
98%
last
26d ago
Corporate Website
LinkedIn
Low volume
98%
last
13d ago
Drug Development
LinkedIn
Low volume
98%
last
11d ago
Pharma and Biotech Software
LinkedIn
Low volume
98%
last
24d ago

Need intent for a specific topic or industry?

We track the full taxonomy across every account in the graph — including themes not shown on this page.

Talk to us

Who's active at Glaukos

verified title on file

Titles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.

Others11 active
researching Laboratory Results
in
researching Patient Care
in
Directorresearching Employer Branding
in
researching Market Access
in
researching Nuclear Medicine
in
Directorresearching Pharmaceuticals
in
Leadershipresearching Drug Development
in
President & Chief Operating Officer
researching Talent Management
in
+ 1 more in Others
Marketing2 active
Sr. Marketing Director, Interventional Keratoconus
researching Patient Care
in
Director, Marketing Operations and Technology
Leadershipresearching Digital Experience
in
+ 2 more in Marketing
Sales1 active
strategic account manager
researching Career Development
in
+ 1 more in Sales

See everyone, not just the first 10

14 people across every department at Glaukos, plus a LinkedIn profile link for each.

Primary products / business lines

LinkedIn company profile

At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

New capability sought

Employee posts (LinkedIn)

Hiring

Top accounts researching Glaukos

names withheld on the public page

These are companies whose own people brought up Glaukos unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.

4,469 companies · 19,343 people are researching Patient Care

Glaukos's own team shows 4 signals on this topic. No one outside Glaukos has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.

  • Health Care7,543 cos · 29,177 people
  • Employer Branding4,643 cos · 15,362 people
Sign up to see which companies →

Buyer profile

company size · seniority

Company size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.

Unlock the buyer profile

Company-size breakdown and buyer seniority mix for accounts researching Glaukos.

Company size breakdown
Buyer seniority mix

Sign up to learn more

Create an account to explore buyer insights as they become available.

Sign up to learn more →

Buying committee functions

Employee job titles (LinkedIn)

Marketing — 2 people; Leadership — 1 person; Sales — 1 person

What's been said

public posts mentioning Glaukos

Up to 9 public excerpts naming Glaukos from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.

LinkedIn

Congratulations to Dr. Thomas Mauger and the team at WVU EYE INSTITUTE for their partnership and recent acquisition of the O2n™ system to perform FDA-approved Epioxa™ (riboflavin 5’-phosphate ophthalmic solution) cross-linking treatment. Thank you for the collaboration—we appreciate all that you do! #DoctorRecognition #PhysicianAppreciation #HealthcareCommunity #Teamwork #Epioxa #O2NSystem #HealthcareInnovation #Glaukos #LivingwithKC #InterventionalKC #InterventionalKeratoconus #IKC

May 2026
LinkedIn

Congratulations to Dr. Joseph Christenbury and his entire team at Eye Consultants of Atlanta for performing the first FDA-approved Epioxa™ (riboflavin 5'-phosphate ophthalmic solution) procedure in Georgia covered by a commercial insurance plan. Their leadership in embracing new therapeutic options continues to elevate care for patients with keratoconus. Epioxa ™ is the first and only epithelium-on oxygen-enriched corneal collagen cross-linking treatment for keratoconus. The most common adverse reaction is conjunctival hyperaemia or redness of the eye. For additional Important Safety Information, please visit https://lnkd.in/gqr4ZjWi . #HealthcareCommunity #Teamwork #HealthcareInnovation #Glaukos #AdvancingCare #ImprovingPatientCare

May 2026
LinkedIn

Congratulations to Dr. Patrick Laber and the team at Raleigh Ophthalmology for their partnership and recent acquisition of the O2n™ system to perform FDA-approved Epioxa™ (riboflavin 5’-phosphate ophthalmic solution) cross-linking treatment. Thank you for the collaboration—we appreciate all that you do! #DoctorRecognition #PhysicianAppreciation #HealthcareCommunity #Teamwork #Epioxa #O2NSystem #HealthcareInnovation #Glaukos #LivingwithKC #InterventionalKC #InterventionalKeratoconus #IKC

May 2026
LinkedIn

We’re hiring at Glaukos Corporation! Seeking an experienced Quality Control Laboratory Manager to join our QC team supporting innovative ophthalmic therapies and combination products. Great opportunity for a strong chemistry leader who enjoys team development, cross-functional collaboration, continuous improvement, and working in a dynamic GMP environment. Apply here: https://lnkd.in/gMPcbCz8

May 2026
LinkedIn

Congratulations to Dr. Vance Thompson and the entire team at Vance Thompson Vision who performed the first FDA-approved Epioxa™ (riboflavin 5'-phosphate ophthalmic solution) procedure yesterday in South Dakota! Their leadership in embracing new therapeutic options continues to elevate care for patients with keratoconus. Epioxa ™ is the first and only epithelium-on oxygen-enriched corneal collagen cross-linking treatment for keratoconus. The most common adverse reaction is conjunctival hyperaemia or redness of the eye. For additional Important Safety Information, please visit https://lnkd.in/gqr4ZjWi . #HealthcareCommunity #Teamwork #HealthcareInnovation #Glaukos #AdvancingCare #ImprovingPatientCare

May 2026
Straight from Glaukos: 6 earnings calls and filings read in full. Leadership's own words on the public record — not analyst commentary.

Strategic priorities

Earnings call; SEC filings

Go to Market; Cash Flow; Market Access

What changed recently

Earnings call; SEC filings

Go to Market; Cash Flow; Market Access

About this data. Glaukos (glaukos.com). Department attribution is 18.75%; remaining activity is grouped under Others. Updated 2026-10-03T14:00:03.490Z.

Not yet computedPer-team narrative summaries